Insider Selling: OptiNose, Inc. (NASDAQ:OPTN) CEO Sells $33,729.04 in Stock

OptiNose, Inc. (NASDAQ:OPTN) CEO Ramy A. Mahmoud sold 6,376 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total value of $33,729.04. Following the completion of the sale, the chief executive officer now owns 126,931 shares in the company, valued at $671,464.99. This represents a 4.78 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

OptiNose Trading Down 2.4 %

Shares of NASDAQ OPTN opened at $5.31 on Friday. The firm has a market cap of $53.42 million, a P/E ratio of -1.26 and a beta of -0.17. The business’s 50 day moving average is $5.93 and its 200-day moving average is $8.82. OptiNose, Inc. has a 1-year low of $4.82 and a 1-year high of $31.50.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. State Street Corp boosted its position in shares of OptiNose by 14.2% in the third quarter. State Street Corp now owns 341,303 shares of the company’s stock valued at $229,000 after acquiring an additional 42,500 shares during the period. GSA Capital Partners LLP bought a new stake in OptiNose in the 3rd quarter valued at about $61,000. Easterly Investment Partners LLC boosted its holdings in OptiNose by 5.0% in the 3rd quarter. Easterly Investment Partners LLC now owns 2,359,239 shares of the company’s stock valued at $1,581,000 after purchasing an additional 113,015 shares during the period. Massachusetts Financial Services Co. MA grew its position in shares of OptiNose by 5.3% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,075,638 shares of the company’s stock worth $2,061,000 after purchasing an additional 155,329 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of OptiNose by 33.7% during the third quarter. Geode Capital Management LLC now owns 1,298,333 shares of the company’s stock worth $870,000 after purchasing an additional 326,918 shares during the period. Institutional investors own 85.60% of the company’s stock.

Analyst Upgrades and Downgrades

OPTN has been the topic of a number of research analyst reports. Lake Street Capital dropped their price target on OptiNose from $45.00 to $17.00 and set a “buy” rating on the stock in a research note on Thursday, January 16th. HC Wainwright increased their price objective on shares of OptiNose from $5.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. Finally, Piper Sandler reduced their target price on shares of OptiNose from $45.00 to $15.00 and set an “overweight” rating for the company in a report on Wednesday, November 13th.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.